Cabaletta Bio, Inc.: Diferență între versiuni

Pagina dedicata companiei Cabaletta Bio, Inc. listata cu simbolul US.CABA

Descriere companie[edit | ]

Cabaletta Bio Inc. (www.cabalettabio.com) is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Grafic actiuni companie[edit | ]

Ultimele stiri despre Cabaletta Bio, Inc. (US.CABA)[edit | ]

• Cabaletta Bio, Inc.